利妥昔单抗联合苯达莫司汀化疗对难治性或复发性滤泡性淋巴瘤和套细胞淋巴瘤患者免疫系统的影响。 - Suppr

Influence of rituximab plus bendamustine chemotherapy on the immune system in patients with refractory or relapsed follicular lymphoma and mantle cell lymphoma.

作者信息

Ito Kaori, Okamoto Masataka, Ando Maiko, Kakumae Yukiko, Okamoto Akinao, Inaguma Yoko, Tokuda Masutaka, Yanada Masamitsu, Yamada Shigeki, Emi Nobuhiko

机构信息

Department of Pharmacy, Fujita Health University Hospital , Toyoake , Japan.

出版信息

Leuk Lymphoma. 2015 Apr;56(4):1123-5. doi: 10.3109/10428194.2014.921298. Epub 2014 Jul 15.

DOI:10.3109/10428194.2014.921298

PMID:24828861

Abstract

摘要

相似文献

Influence of rituximab plus bendamustine chemotherapy on the immune system in patients with refractory or relapsed follicular lymphoma and mantle cell lymphoma.

Leuk Lymphoma. 2015 Apr;56(4):1123-5. doi: 10.3109/10428194.2014.921298. Epub 2014 Jul 15.

Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial.

Lancet Oncol. 2016 Jan;17(1):57-66. doi: 10.1016/S1470-2045(15)00447-7. Epub 2015 Dec 5.

A rare composite lymphoma: follicular and in situ mantle cell.

Ann Hematol. 2016 Aug;95(8):1351-2. doi: 10.1007/s00277-016-2680-4. Epub 2016 Apr 22.

Successful retreatment with 3-week rituximab-bendamustine with high-dose dexamethasone in patients with relapsed/refractory mantle cell lymphoma.

Ann Hematol. 2019 Jun;98(6):1519-1520. doi: 10.1007/s00277-018-3588-y. Epub 2018 Dec 13.

Safety and efficacy of Temsirolimus in combination with Bendamustine and Rituximab in relapsed mantle cell and follicular lymphoma.

Leukemia. 2015 Aug;29(8):1695-701. doi: 10.1038/leu.2015.60. Epub 2015 Mar 13.

Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials.

Lancet Haematol. 2017 Apr;4(4):e176-e182. doi: 10.1016/S2352-3026(17)30028-5. Epub 2017 Mar 15.

Prolonged lymphocytopenia after bendamustine therapy in patients with relapsed or refractory indolent B-cell and mantle cell lymphoma.

Blood Cancer J. 2015 Oct 23;5(10):e362. doi: 10.1038/bcj.2015.86.

High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG).

Leuk Lymphoma. 2007 Jul;48(7):1299-306. doi: 10.1080/10428190701361828.

Sustained CD4 and CD8 lymphopenia after rituximab maintenance therapy following bendamustine and rituximab combination therapy for lymphoma.

Leuk Lymphoma. 2015;56(11):3216-8. doi: 10.3109/10428194.2015.1026818. Epub 2015 May 12.

Bendamustine and the immune system: a wolf in sheep's clothing?

Leuk Lymphoma. 2015 Apr;56(4):837-8. doi: 10.3109/10428194.2015.1024942.

引用本文的文献

Changes of T cell subsets across treatments associated with prognosis in newly diagnosed follicular lymphoma.

Sci Rep. 2024 Nov 11;14(1):27576. doi: 10.1038/s41598-024-79173-w.

Infections in patients with mantle cell lymphoma.

Hemasphere. 2024 Jul 8;8(7):e121. doi: 10.1002/hem3.121. eCollection 2024 Jul.

Cytomegalovirus Occurrence and Time-to-onset Analysis Under Bendamustine With Anti-CD20 Antibodies Using the JADER Database.

In Vivo. 2024 Mar-Apr;38(2):923-927. doi: 10.21873/invivo.13520.

Clinical outcomes in transplant-eligible patients with relapsed or refractory diffuse large B-cell lymphoma after second-line salvage chemotherapy: A retrospective study.

Cancer Med. 2023 Sep;12(17):17808-17821. doi: 10.1002/cam4.6412. Epub 2023 Aug 28.

Strong Humoral but Not Cellular Immune Responses against SARS-CoV-2 in Individuals with Oncohematological Disease Who Were Treated with Rituximab before Receiving a Vaccine Booster.

Cancers (Basel). 2022 Nov 10;14(22):5537. doi: 10.3390/cancers14225537.

Serum IgG and lymphocyte counts are useful for the early detection of infection in patients receiving bendamustine-rituximab therapy.

J Clin Exp Hematop. 2022 Jun 28;62(2):91-98. doi: 10.3960/jslrt.21031. Epub 2022 Mar 12.

Real-world evidence of cytomegalovirus reactivation in non-Hodgkin lymphomas treated with bendamustine-containing regimens.

Open Med (Wars). 2021 Apr 21;16(1):672-682. doi: 10.1515/med-2021-0274. eCollection 2021.

Influence of R-CHOP Therapy on Immune System Restoration in Patients with B-Cell Lymphoma.

Oncology. 2016;91(6):302-310. doi: 10.1159/000449251. Epub 2016 Sep 29.

Bendamustine added to allogeneic conditioning improves long-term outcomes in patients with CLL.

Bone Marrow Transplant. 2017 Jan;52(1):28-33. doi: 10.1038/bmt.2016.204. Epub 2016 Sep 5.

A case of Pneumocystis jiroveci pneumonia after bendamustine-based chemotherapy for refractory diffuse large B-cell lymphoma.

Blood Res. 2016 Mar;51(1):61-3. doi: 10.5045/br.2016.51.1.61. Epub 2016 Mar 25.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Influence of rituximab plus bendamustine chemotherapy on the immune system in patients with refractory or relapsed follicular lymphoma and mantle cell lymphoma.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献